Reply to: “mRECIST for systemic therapies: More evidence is required before recommendations could be made”

Robert Montal; Riccardo Lencioni; Josep M. Llovet

doi:10.1016/j.jhep.2017.03.004

Related publications

Article2022

Molecular pathogenesis and systemic therapies for hepatocellular carcinoma

Josep M. Llovet, Roser Pinyol, Robin Kate Kelley, Anthony B. El-Khoueiry, Helen L. Reeves, Xin Wei Wang, Gregory J. Gores, Augusto Villanueva

Nature Cancer

Letter2020

Triple artemisinin-based combination therapies for malaria: proceed with caution – Authors' reply

Rob W. van der Pluijm, Aung Pyae Phyo, Dysoley Lek, Sir Nicholas White, Arjen M. Dondorp

The Lancet

Article2020

Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma

Johann von Felden, Amanda J. Craig, Teresa García‐Lezana, Ismaïl Labgaa, Philipp K. Haber, Delia D’Avola, Amon Asgharpour, Douglas T. Dieterich, Antoinette Bonaccorso, Miguel Torres‐Martín, Daniela Sia, Max W. Sung, Parissa Tabrizian, Myron Schwartz, Josep M. Llovet, Augusto Villanueva

Oncogene

Article2008

Lipocalin 2 is required for BCR-ABL-induced tumorigenesis

Xiaohong Leng, Hui‐Kuan Lin, T Ding, Yingjun Wang, Yun Wu, S. Klumpp, Tong Sun, Yi Zhou, Paola Monaco, John W. Belmont, Alan Aderem, Akira Shizuo, Roland K. Strong, Ralph B. Arlinghaus

Oncogene

Article2014

Is evidence actually evidence?

Paul Cummins, Patrick W. Serruys

EuroIntervention